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A high-performance liquid chromatography (HPLC) method utilizing triple quadrupole mass
spectrometry (MS) detection was developed and validated for the simultaneous measurement
of the intracellular nucleoside 59-triphosphate anabolites of zidovudine (ZDV-TP), lamivudine
(3TC-TP), and stavudine (d4T-TP). These compounds were extracted from patient peripheral
blood mononuclear cells (PBMCs) which are the sites of HIV replication and drug action.
Ion-exchange solid phase extraction (SPE) followed by enzymatic digestion with alkaline
phosphatase was utilized to yield the measurable nucleoside forms of the nucleotides.
Reversed phase C-18 SPE with addition of a nucleoside internal standard, 39-azido-29,39-
dideoxyuridine (AzdU) allowed for the indirect measurement of the original 59-triphosphate
concentration by HPLC/MS/MS. Quantitation was performed from calibration curves gener-
ated from authentic 59-triphosphate standards spiked in PBMCs from healthy volunteers.
Analytical range for the three 59-triphosphates was equivalent to 50–45,000 pg. Mean
interassay accuracies for 3TC-TP, d4T-TP, and ZDV-TP (n . 90) were 99.4%, 100.1%, and
108.0%, respectively. Mean interassay precisions (%C.V.) for 3TC-TP, d4T-TP, and ZDV-TP
(n . 90) were 8.8%, 10.4%, and 8.2%, respectively. Recovery of the extraction method was
79.2%, 83.1%, and 98.3% for 3TC-TP, d4T-TP, and ZDV-TP, respectively. This method can be
utilized to measure the intracellular 59-triphosphate levels in HIV infected patients receiving
antiretroviral therapy containing the nucleoside reverse transcriptase inhibitors 3TC, d4T, or
ZDV. (J Am Soc Mass Spectrom 2000, 11, 1134–1143) © 2000 American Society for Mass
Spectrometry
Treatment of HIV infected patients with nucleo-side reverse transcriptase inhibitors (NRTI) hasbeen a standard practice since the approval of
Zidovudine. Each NRTI demonstrates its own individ-
ual pharmacokinetics, pharmacodynamics, efficacy,
and toxicity, but all share a common antiviral mecha-
nism. Peripheral blood mononuclear cells (PBMCs) in-
clude T lymphocytes, macrophages, and monocytes and
express the CD4 receptor, which is the cellular target of
HIV invasion. Each NRTI must be initially converted to
the intracellular 59-monophosphate which is phosphor-
ylated to the 59-diphosphate and finally to the active
59-triphosphate nucleotide by host cell nucleoside ki-
nases. The NRTI 59-triphosphate competitively inhibits
HIV reverse transcriptase with incorporation into the
proviral DNA resulting in DNA chain termination and
prevention of viral replication. Efficiency of phosphor-
ylation is dependent on such factors as extracellular
drug concentrations, intracellular kinase activity, repli-
cation status of host cells (activated vs. resting), and
competition between endogenous nucleosides and NR-
TIs for nucleoside kinases, as well as drug–drug inter-
actions [1–6]. Development of resistant HIV strains
occurs after extended treatment with a single NRTI
drug. Poor response indexed by low CD4 lymphocyte
counts and high HIV RNA levels in individuals who
developed resistance fostered the current practice of
combination therapy. By utilizing two or more NRTIs in
combination with a protease inhibitor (PI), significant
and prolonged decreases in viral RNA has been ob-
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served [7, 8]. A reconstitution of the immune system
also occurs, characterized by sustained CD4 lympho-
cyte counts after initiation of triple combination therapy
[9]. Due to highly individualized phosphorylation of
the NRTIs, a poor correlation between plasma drug
levels and intracellular triphosphate levels has been
reported [10]. However, intracellular levels of NRTI
59-triphosphates (NRTI-TPs) have demonstrated a sig-
nificant inverse relationship with HIV RNA levels [11,
12].
The combination of anabolic interactions, viral resis-
tance, drug–drug interactions, and poor relationship
between plasma drug levels and patient outcome have
prompted the development of methodologies to mea-
sure intracellular mono-, di-, and triphosphate levels in
PBMCs. Methods utilized to measure these compounds
require sensitivity and selectivity. Selectivity is a para-
mount concern to distinguish between multiple NRTI-
TPs and those of endogenous intracellular nucleotides.
The quantitation of intracellular NRTI-TPs has been
reported using a variety of methodologies. These in-
clude radioimmunoassay (RIA) [13, 14], anion exchange
HPLC [15,16], HPLC with UV detection [17], combina-
tion of HPLC and RIA [18, 19], and enzymatic assay [20,
21]. None of these methods demonstrated the ability to
simultaneously measure more than one NRTI triphos-
phate compound per sample. A single drug assay per
sample can be limiting in combination therapy where
10–15 mL of blood must be drawn to obtain adequate
numbers of PBMCs for sensitive measurement of NRTI-
TPs.
Direct analysis of the intracellular phosphorylation
products of NRTIs by high-performance liquid chroma-
tography (HPLC)/mass spectrometry (MS) is hindered
by the high concentrations of nonvolatile salts required
to resolve the mono-, di-, and triphosphates present.
Triphosphates of NRTIs are also unstable at room
temperature compared to their corresponding nucleo-
side forms and are quickly degraded to the di- and
monophosphates. The use of a volatile ion pairing
reagents (1 mM dimethylhexylamine), in conjunction
with reversed phase HPLC/MS/MS in negative ioniza-
tion mode allowed the separation of the phosphoryla-
tion anabolites of Penciclovir, a NRTI used in the
treatment of herpes [22]. However, no analysis in PB-
MCs or sensitivity of analysis was reported.
Herein we describe a validated HPLC triple quadru-
pole mass spectrometry method for the simultaneous
measurement of intracellular 3TC, d4T, and ZDV 59-
triphosphates. The mass spectrometer utilizes an atmo-
spheric pressure Ionspray interface whereby the HPLC
eluent from a miniature C-18 column is directly ana-
lyzed by multiple reaction monitoring (MRM). Identifi-
cation and quantitation of 3TC-TP, d4T-TP, and
ZDV-TP is performed against known standards ex-
tracted from PBMCs after addition of a nucleoside
internal standard, AzdU. The analytical range for the
method is 50–45,000 pg, approximately equivalent to
0.2–200 pmol for each of the NRTI-TPs measured. This
method is currently being utilized to measure 3TC-TP,
d4T-TP, and ZDV-TP in HIV-infected patients to inves-
tigate the intracellular pharmacokinetics and pharma-
codynamics that occur using combination therapy for
the treatment of HIV infection.
Methods
Materials and Reagents
Authentic standards of (-)-29,39-deoxy-39-thiacytidine-
59-triphosphate (3TC-TP), 29,39-didehydro-39-deoxythy-
midine-59-triphosphate (d4T-TP), and 39-azido-39-deoy-
thymidine-59-triphosphate (ZDV-TP) were purchased
from Moravek Biochemicals (Brea, CA). The internal
standard compound, 39-azido-29,39-dideoxyuridine
(AzdU, CS-87) was a gift from Dr. Raymond Schinazi,
Emory University School of Medicine (Atlanta, GA).
Methanol, acetonitrile, potassium chloride, and ammo-
nium acetate were HPLC grade and purchased from
Fisher Scientific (Fairlawn, NJ). Water was supplied by
an in-house Milli-Q deionization system. All HPLC
solvents and solid phase extraction solutions were
vacuum filtered through 0.2 mm, Supor-200, 47 mm
filters, Gelman Sciences (Ann Arbor, MI). Alkaline
phosphatase (calf intestine) was purchased from Worth-
ington Biochemical (Lakewood, NJ). Anion exchange,
Sep Pak QMA cartridges (100 mg 3 1 mL) and reversed
phase, Sep Pak C-18 cartridges (100 mg 3 1 mL) were
purchased from Waters (Millford, MA). PBMCs were
isolated from the whole blood of healthy drug free
volunteers and HIV infected patients. Stock solutions of
PBMCs containing 500 3 106 cells were prepared from
the resulting pellet of the healthy donors by adding an
appropriate volume of ice-cold 60% methanol, and
stored at 280 °C. This solution was used as the matrix
for preparing standards and controls.
Preparation of Standards and Controls
Separate master stock solutions for standards and con-
trols of 3TC-TP, d4T-TP, and ZDV-TP were prepared at
87.0, 44.6, and 75.0 mM, respectively. Master stocks were
diluted and aliquoted into working stock solutions of
43.5 nM of 3TC-TP, 44.6 nM of d4T-TP, and 37.5 nM of
ZDV-TP for both calibrators and controls in 60% meth-
anol and were stored at 280 °C. Calibration standards
were prepared by spiking 10 3 106 PBMCs with vol-
umes of the standard working stock solutions to
achieve corresponding nucleoside equivalent amounts
of 0, 50, 100, 500, 1000, 2500, 5000, 15,000, and 45,000
pg/standard. This is equivalent to approximately 0.2–
200 pmol for each NRTI-TP. Quality control samples
were prepared by diluting the control working stock
solutions into 10 3 106 PBMCs to achieve amounts of 0,
80, 200, and 2000 pg/control. This is equivalent to
approximately 0, 0.3, 0.8, and 8.0 pmol of each NRTI-TP.
All patient samples, calibrators, and controls were ali-
quoted and stored at 280 °C.
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A stock AzdU internal standard solution was pre-
pared at a concentration of 20 mg/mL in Milli-Q water
and subsequently diluted to a final working concentra-
tion of 1 mg/mL in Milli-Q water and stored at 2–8 °C.
Sample Preparation
A minimum of 15 mL of whole blood was collected
from patients into two Vacutainer CPT tubes (Becton
Dickinson, Franklin Lakes, NJ) and immediately centri-
fuged at 1500 3 g for 20 min at room temperature. The
upper layer containing plasma and PBMCs was recov-
ered and centrifuged at 1500 3 g for 10 min to pellet
the cells. The plasma was removed and the cells were
re-suspended in 0.2 mL of ice-cold 60% methanol. The
samples were immediately stored on dry ice and
shipped to our facility. Samples were unpacked and
store at 280 °C until extraction. Calibrators, controls,
and patient PBMC samples were removed from 280 °C
storage and thoroughly mixed, then sonicated for 10
min and centrifuged at 14,000 3 g for 5 min. The 60%
methanol was removed to corresponding labeled 1.5
mL eppendorf tubes and placed on ice. The cell pellets
were re-suspended and extracted by sonication with an
additional 0.2 mL of ice-cold 60% methanol for 10 min.
The samples were centrifuged again at 14,000 3 g for 5
min and the 60% methanol portions were combined and
evaporated to dryness under nitrogen at room temper-
ature. Fractionation of the NRTIs and phosphorylated
derivatives was performed by anion exchange solid
phase extraction (IE-SPE) using increasing molar con-
centrations of potassium chloride (KCl) in the following
manner. The samples were reconstituted with 0.3 mL of
Milli-Q water and loaded onto the Waters QMA anion
exchange columns and extracted at a rate of approxi-
mately 0.25 mL/min. The remaining nonphosphory-
lated NRTIs were eluted with 0.5 mL of Milli-Q water,
followed by a 0.5 mL of water and 0.2 mL of 20 mM KCl
wash. The diphosphocholine derivative of 3TC was
eluted with 0.4 mL of 60 mM KCl followed by a 0.1 mL
wash of 100 mM KCl. The NRTI monophosphates were
eluted with 0.3 mL of 100 mM KCl, followed by an
additional 0.1 mL of 100 mM KCl as wash. The NRTI
diphosphates were eluted with 0.4 mL of 120 mM KCl.
The NRTI triphosphates were finally eluted with 0.5 mL
of 400 mM KCl. A structurally suitable triphosphate of
a currently nonprescribed nucleoside analog was not
available for use as the internal standard, therefore
AzdU was chosen. AzdU is the uridine form of ZDV
and is not currently used as a therapeutic agent, pre-
cluding it from possible detection in samples of HIV
infected patients. Into each triphosphate fraction col-
lected, 0.01 mL of the 1 mg/mL working AzdU internal
standard solution and 50 units of calf intestine alkaline
phosphatase was added to each tube and sealed. All
samples, calibrators, and controls were incubated over-
night (14–18 h) at 37 °C. After incubation, digest were
stored at 220 °C until C-18 SPE extraction.
The resulting NRTIs from the alkaline phosphatase
digest of the NRTI-TP fraction were extracted with
Waters, C-18 SPE columns. Briefly, digested samples
were loaded onto the C-18 SPE columns after condition-
ing with 2 3 1 mL washes of 1:1 acetonitrile:methanol
and then 2 3 1 mL washes of 20 mM ammonium
acetate (NH4OAc). Extraction was performed at a rate
of approximately 0.25 mL/min. Each column was
washed with 1 mL of 20 mM NH4OAc (Note: additional
volumes of 20 mM NH4OAc will decrease the recovery
of 3TC by 20%–30%). The NRTIs were eluted from the
C-18 SPE column with 2 3 0.5 mL volumes of 1:1
methanol:acetonitrile. Each sample was evaporated to
dryness under nitrogen at room temperature. The sam-
ples were reconstituted with 0.02 mL of 90:10 (v/v) 20
mM NH4OAc:acetonitrile and stored at 2–4 °C until
HPLC/MS/MS analysis.
IS-HPLC/MS/MS Analysis
10 mL of the calibrators, controls, and samples were
injected onto a Columbus, 100 3 1 mm i.d., 5 m C-18
reversed phase HPLC column (Phenomenex, Torrance,
CA) at room temperature. This resulted in half of the
total nucleoside extracted being injected on column.
The mobile phase was 86:14 (v/v) 10 mM NH4OAc:
acetonitrile at a flow rate of 0.05 mL/min as delivered
by a model HP 1050 quaternary pump (Agilent Tech-
nologies, Palo Alto, CA). These proportions of acetoni-
trile and 10 mM NH4OAc produced full chromato-
graphic resolution of the four analytes in under 7 min
while providing adequate ionization for formation of
either the [M 1 NH4]
1 or [M 1 H]1 of the nucleosides.
The flow stream from the column was directly con-
nected to the Ionspray interface of a PE Sciex API-III
triple quadrupole mass spectrometer (Perkin Elmer,
Toronto, Canada). The HPLC eluent was nebulized at a
flow rate of 0.6 L/min off-axis to the source orifice.
Acquisition was performed in positive ionization mode
at an orifice setting optimized to 50 eV, which produced
the highest abundance for the chosen [M 1 H]1 of 3TC,
d4T, and ZDV when monitored in Q1. The first quad-
rupole (Q1) was programmed to select the [M 1 H]1
ions of 3TC, d4T, and ZDV at m/z 230.2, 225.2, and 268.2,
respectively, and the [M 1 NH4]
1 ions of AzdU at m/z
271.2. The [M 1 NH4]
1 adduct of AzdU was chosen
because it produced chromatographic peak areas for 5
ng injected on column that provided calibration re-
sponse factors in the 1 to 5 range for all three analytes at
mid-concentration range. The collision cell (Q2) gas, a
mixture of 9:1 argon:nitrogen, was set to a thickness of
300 3 1012 molecules/cm2. Collision energy was opti-
mized at 36 eV producing the highest abundance of
product ions in Q1. Subsequent product ions generated
from the collision of the Q1 ions with the collision gas in
Q2 were selected by the third quadrupole (Q3) for
identification and quantitation. Product ions monitored
were m/z 112.2 (3TC), 113.2 (AzdU), and 127.2 (d4T and
ZDV) corresponding to the [B 1 2H]1 adducts of the
NRTI bases. Ion monitoring dwell time for all analytes
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was optimized to 500 ms. A product ion scan for each
analyte demonstrating the fragmentation to their corre-
sponding [B 1 2H]1 adduct under these conditions is
provided in Figure 1. Sensitivity and selectivity were
enhanced by programming the instrument to select for
3TC and d4T ions for the initial 3.5 min of the chro-
matogram and switching to AzdU and ZDV selection
for the remaining 3 min. Peaks in the HPLC/MS/MS
chromatogram were integrated and concentrations
were calculated from a calibration curve generated from
the injections of standards ranging from 50 to 45,000 pg.
All peak integration, calibration, and raw result calcu-
lations were performed by McQuan, a HPLC/MS quan-
titation software package (Perkin Elmer, Toronto Can-
ada). The calibration curve was constructed with
standard amount (x axis) versus standard peak area/
internal standard peak area (y axis) response factors.
The curve was weighted to 1/x for optimizing accuracy
of the lower concentrations expected from the intracel-
lular 59-triphosphates of d4T and ZDV. Results from the
quality control samples were evaluated to determine
the accuracy of the method. Final results for patient
samples were expressed as either pmol/106 PBMCs for
3TC-TP or fmol/106 PBMCs for d4T-TP and ZDV-TP.
Results and Discussion
Our foremost objective in developing the method was
to provide a simultaneous analysis of the 59-triphos-
phates of 3TC, d4T, and ZDV. The method was devel-
oped to be selective and sensitive with a large analytical
range and high sample throughput. The validation
protocol was designed to encompass the concentration
ranges reported in the literature. The HPLC/MS/MS
method was validated by performing analysis on a
minimum of five replicates of each NRTI-TP spiked
PBMC control for six separate assays. The method
validation process included the verification of specific-
ity, analytical range, linearity, limit of detection, limit of
quantitation, recovery, interassay accuracy, and preci-
sion for each analyte.
Specificity
Specificity was developed into the method by first
utilizing a triple quadrupole MRM detection technique,
whereby analyte specific ions were selected in both the
Q1 and Q3 regions of the mass spectrometer. Second,
the chromatographic separation was optimized to per-
form acceptable chromatographic resolution of the four
compounds monitored, diminishing possibilities of ion
quenching between analytes at high and low concentra-
tions. Retention times for 3TC, d4T, AzdU, and ZDV
were approximately 2.1, 2.4, 4.0, and 5.5 min, respec-
tively. To verify the selectivity, unspiked PBMCs from
healthy donors were extracted and analyzed for possi-
ble interference from endogenous nucleotides/nucleo-
sides. Figure 2 depicts total reaction monitoring traces
collected under the conditions described above for a 500
pg standard and a PBMC blank. Additionally, injections
of other NRTIs potentially used in HIV treatment were
injected to determine specificity. 5 ng of ddC, ddI, and
ddA (the corresponding active intracellular nucleoside
59-triphosphate form of ddI) demonstrated no interfer-
ence with the HPLC/MS/MS method (data not shown).
Specificity of the IE-SPE fractionation was previously
verified by our group through analysis of radiolabeled
monophosphate (MP), diphosphate (DP), and triphos-
phate (TP) fractions derived from incubation of [methyl-
3H]3TC with phytohemagglutinin stimulated PBMC
cultures. IE-SPE fractions were injected onto a strong
anion exchange HPLC system with radioactive detec-
tion. Only one peak per fraction with appropriate
retention time was detected [17]. Additionally, the
specificity of the triphosphate fraction was verified by
injection of IE-SPE/C18-SPE MP and DP fractions of the
45,000 pg NRTI-TP calibration standard. No 3TC, d4T,
or ZDV were detected in either of the fractions, dem-
onstrating only the NRTI-TP was eluted in the 400 mM
KCl elution. Direct spiking of PBMCs with MP and DP
of 3TC, d4T, and ZDV was not possible due to unavail-
ability of pure standards.
Analytical Range and Linearity
The analytical range of the HPLC/MS/MS method was
determined by spiking 10 3 106 PBMCs with 3TC-TP,
d4T-TP, and ZDV-TP over a range of 10–50,000 pg. The
samples were extracted and analyzed as described. An
amount versus response factor (area of analyte peak/
area of internal standard peak) curve was constructed
for each compound with regression analysis performed
as a linear fit forced through zero. A forced zero
intercept was chosen for linearity to evaluate possible
error in the lower concentration range of the curve. All
back-calculated values from the fitted curve were
within 10% of their nominal value between 50 and
50,000 pg for each analyte. The analytical range for d4T
was equal to 50–50,000 pg (0.2–223 pmol). The range for
ZDV was equivalent to 50–50,000 pg (0.19–187 pmol),
and 10–50,000 (0.04–218 pmol) for 3TC. Regression
coefficients (r2) for all three compounds were not less
than 0.997. For the analysis of NRTI-TPs in patients, the
calibration curve was formulated to a range of 50–
45,000 pg for each compound. A calibration curve was
generated for each of six assays with r2 values of not
less than 0.995 for any analyte curve. Curves were
weighted to 1/x to optimize the accuracy of predicted
low concentrations of d4T-TP and ZDV-TP in patient
PBMC samples. Typical calibration curves for 3TC, d4T,
and ZDV generated from spiked PBMCs are shown in
Figure 3. Inset contains view of y-intercept region and
curve fit at lower amounts (50–1000 pg).
Limit of Detection and Quantitation
The detection limit for 3TC, d4T, and ZDV was deter-
mined from the signal to noise level (S/N) demon-
strated from the analysis of spiked PBMC samples. The
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Figure 1. Molecular structure and product ion spectra for 3TC, d4T, AzdU, and ZDV. The mass
spectra were generated by collision of the Q1 selected ions for each compound with a mixture of argon
and nitrogen in the Q2 region of the triple quadrupole mass spectrometer. Axes: y 5 relative intensity
and x 5 m/z.
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limit of detection (LOD) was defined as the amount per
injection, which demonstrated a S/N of not less than 3
as calculated by the McQuan software. The limit of
quantitation (LOQ) was assigned as the injected
amount which demonstrated a coefficient of variation
(%C.V.) of ,15% for a minimum of six replicates
performed over three assays. The LOD and LOQ with
subsequent S/N and %C.V. values for each are pro-
vided in Table 1. The method demonstrated acceptable
quantitative precision at the minimum detectable
amount.
Recovery
As stated, AzdU is a nucleoside analog with character-
istics that make it an acceptable quantitative internal
standard. It however must be added to the sample after
ion exchange SPE to prevent loss in the initial addition
of the sample on the IE-SPE column. Recovery valida-
tion therefore was performed against nucleoside (non-
phosphorylated) standards of 3TC, d4T, and ZDV di-
rectly spiked into the IE-SPE and C18-SPE extracts of
drug-free PBMCs. AzdU internal standard was added
to each calibrator prior to evaporation and reconstituted
in mobile phase. This represented 100% IE-SPE/enzy-
matic digestion/C18-SPE recovery, while maintaining
the same analysis/recovery matrix between NRTI-TP
controls and nucleoside calibrators. Six replicates of the
low, medium, and high NRTI-TP controls prepared in
PBMCs were extracted as described and prepared for
HPLC/MS/MS analysis. The control samples were
Figure 2. Total reaction monitoring traces collected under the MRM conditions described for an
extracted nucleotide calibrator containing 500 pg each of d4T-TP, 3TC-TP, and ZDV-TP with AzdU
added as internal standard and a blank nucleotide control sample, both containing 10 3 106 PBMCs.
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quantitated against the PBMC matrix spiked nucleoside
calibration curve. Recovery at each level was calculated
from the measured value divided by the nominal value
3100. Recovery for 3TC and d4T appeared to be con-
centration dependent. Values for 3TC decreased from
90.6% to 68.6% over the range of 80 to 2000 pg.
Recovery decreased from 95.5% to 70.5% for d4T over
the same range. ZDV recovery remained above 93% for
the three control concentrations. This concentration
dependant recovery was due to the loss of the more
polar analytes from the C-18 SPE cartridge upon wash-
ing with 1 ml of 20 mM NH4OAc. Conversely, failure to
wash with 20 mM NH4OAc resulted in decreased
sensitivity for all analytes due to excessive residual KCl
(400 mM) in the final sample, thereby suppressing
molecular ionization in the mass spectrometer interface.
Utilization of NRTI-TP standards in PBMCs which
undergo the same extraction procedure as unknowns
and controls, normalized this effect and maintained
acceptable sensitivity, accuracy, and precision for the
assay over the entire analytical range. The recovery data
and statistics are provided in Table 2.
Accuracy and Precision
Six replicates of the low, medium, and high controls
were extracted and analyzed on six separate occasions
against calibration curves formulated as described. A
minimum of 30 control samples for each level were
used to calculate interassay accuracy and precision
Figure 3. Combined calibration curves for 3TC (filled circle), d4T (filled square), and ZDV (filled
triangle). Range equal to 50–45,000 pg (inset 5 50–1000 pg). Regression coefficients (r2) for curves
weighted to 1/x are equal to 0.998, 0.997, and 0.999, respectively, for 3TC, d4T, and ZDV.
Table 1. Limit of detection (LOD) and limit of quantitation
(LOQ) for 3TC-TP, d4T-TP, and ZDV-TP by HPLC/MS/MS.
Amount injected on column in picograms (pg)
Compound
LOD
(pg) S/N
LOQ
(pg) % C.V. (n)
3TC-TP 5 9.5 5 13.55 (9)
d4T-TP 25 3.5 25 10.29 (8)
ZDV-TP 25 4.5 25 7.47 (6)
Table 2. Recovery of NRTI-TP spiked PBMCs vs. NRTIs in
methanol (n 5 6 for each level)
Amount
(pg)
3TC
%
Recovery
(% C.V.)
d4T
%
Recovery
(% C.V.)
ZDV
%
Recovery
(% C.V.)
80 90.6 (6.4) 95.5 (7.7) 106.0 (4.8)
200 78.3 (12.7) 83.3 (5.8) 93.3 (3.8)
2000 68.6 (6.5) 70.5 (4.1) 95.7 (1.1)
Mean 79.2 83.1 98.3
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values. The interassay accuracy of the method was
expressed as the mean of the individual control values
for each compound relative to their nominal values.
Overall accuracy was expressed as the mean of low,
medium, and high control accuracy values for each
NRTI. Interassay accuracy was not less than 95.6% for
the low, medium, and high controls for all three NRTIs.
Overall accuracy was 99.4%, 100.1%, and 108.0% for
3TC, d4T, and ZDV, respectively. Interassay precision
was calculated as the mean coefficient of variation
(%C.V.) for each control of each compound. Overall
precision was calculated as the mean of low, medium,
and high control values for each NRTI. Interassay
precision was not more than 12.4% for the low, me-
dium, and high controls. Overall precision was 8.8%,
10.4%, and 8.2% for 3TC, d4T, and ZDV, respectively.
Table 3 summarizes the inter-assay accuracy and preci-
sion for 3TC, d4T and ZDV.
Patient Sample Analysis
PBMC samples drawn monthly for two individuals
receiving combination anti-HIV therapy of either 3TC,
d4T, and the protease inhibitor Indinavir, or 3TC, d4T,
and the protease inhibitor Nelfinavir, were analyzed by
HPLC/MS/MS. No PBMC counts were determined
prior to dissolution in 60% methanol. The concentration
of each NRTI-TP/106 PBMCs was normalized to a value
of 28 3 106 PBMCs per sample (102 PBMCs samples
submitted for patients receiving similar therapy had
PBMC counts equal to 28.1 6 10.9). These samples
exhibited 3TC-TP concentrations ranging from 2.6 to 5.5
pmol/106 cells. Reported concentrations of 3TC-TP
ranged from 2 to 7 pmol/106 cells in PBMCs of patients
receiving daily doses of 300 mg 3TC [14, 17]. The
measured d4T-TP concentrations ranged from 6.3 to
22.8 fmol/106 cells. Preliminary data from our group for
individuals receiving combination therapy of 3TC and
d4T demonstrated concentrations ranging from 60 to
220 fmol/10 3 106 PBMCs [11]. Table 4 provides the
analytical results obtained.
A single PBMC preparation was submitted for a
patient receiving total NRTI combination therapy of
d4T, 3TC, ZDV, and DDI. Concentrations of 3TC-TP,
d4T-TP, and ZDV-TP were equal to 3.2 pmol/106 PB-
MCs for 3TC-TP, 21.5 fmol/106 PBMCs of d4T-TP, and
20.3 fmol/106 PBMCs of ZDV-TP. The concentrations of
ZDV-TP reported in the literature ranged from 5 to 500
fmol/106 cells [10, 12, 13, 18, 19, 21]. Although this
clinical practice is no longer recommended due to the
demonstrated negative drug–drug interaction between
ZDV and d4T [23], it demonstrates the ability to simul-
taneously measure the intracellular triphosphates of
3TC, d4T, and ZDV. Figure 4 provides the reaction
monitoring traces for each analyte in this sample.
Conclusion
The d4T-TP and ZDV-TP concentrations described are
200–500 times lower than those of 3TC-TP, demonstrat-
ing the need for sensitivity, accuracy, and precision
over a large analytical range. These criteria cannot be
met with methodologies used to date without dilution
and/or multiple analyses from a large sample volume.
The speed of analysis for this HPLC/MS/MS method
can greatly increase the number of samples analyzed.
The demonstrated analytical range of the method
would also facilitate the measurement of intracellular
59-monophosphate levels of ZDV and d4T after valida-
tion with suitable 59-monophosphate standards. The
intracellular 59-monophosphate of ZDV in vivo has
been reported to be approximately 100 times higher
Table 3. Interassay accuracy (%) and precision (% C.V.) for
PBMCs spiked with nucleoside triphosphates equivalent to 80,
200, and 2000 pg of 3TC, d4T, and ZDV (n 5 total number of
control samples performed over six analyses)
Compound
(n)
80 pg 200 pg 2000 pg Overall
%
%
C.V. %
%
C.V. %
%
C.V. %
%
C.V.
3TC (94) 95.6 11.3 100.8 9.1 101.8 6.0 99.4 8.8
D4T (92) 99.0 12.4 103.4 9.8 97.8 8.9 100.1 10.4
ZDV (92) 110.3 9.3 108.9 10.2 104.7 5.1 108.0 8.2
Table 4. HPLC/MS/MS results of two HIV-infected patients treated with combination of 3TC and d4T with a protease inhibitor
Patient
Sample
date
Treatment
regimen
3TC-TP
(pmol)
3TC-TP
(pmol/106)
d4T-TP
(pmol)
d4T-TP
(fmol/
106)
1 12/30/97 d4T/3TC/IND 119.3 4.3 0.457 16.3
1/21/97 d4T/3TC/IND 154.8 5.5 0.637 22.8
2/10/98 d4T/3TC/IND 148.4 5.3 0.585 20.9
3/10/98 d4T/3TC/IND 107.9 3.9 0.176a 6.3
4/7/98 d4T/3TC/IND 91.6 3.3 0.289 10.3
5/6/98 d4T/3TC/IND 72.2 2.6 ND ND
2 3/4/98 d4T/3TC/NLF 102.7 3.7 0.335 12.0
4/7/98 d4T/3TC/NLF 117.2 4.2 0.349 12.5
6/2/98 d4T/3TC/NLF 96.6 3.5 0.290 10.4
aExtrapolated below lowest calibrator of 0.22 pmol from 1/x weighted curve. ND 5 none detected below signal/noise of 3. IND 5 Indinavir, NLF 5
Nelfinavir. Concentrations of NRTI-TP/106 PBMCs normalized to 28 3 106 PBMCs.
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than the 59-triphosphate, whereas the 59-monophos-
phate level of d4T is similar to that of the 59-triphos-
phate [14, 23]. The exceptional sensitivity for 3TC-TP
(0.04 pmol) could be used in the intracellular measure-
ment of pediatric samples as well as intracellular phar-
macokinetic studies where multiple large sample vol-
umes cannot be drawn.
Herein we have demonstrated the simultaneous
measurement of intracellular triphosphates 3TC, d4T,
and ZDV in PBMCs of HIV infected patients by HPLC/
MS/MS. This technology can provide data to support
the pharmacodynamic studies of NRTI therapy as part
of combination regimens in HIV infected patients. The
need for rapid, selective, and sensitive analysis will
continue to grow in order to properly study the effects
of anti-HIV drugs at target sites of HIV replication.
Whether these are measured in the circulating PBMC or
other tissues, HPLC/MS/MS can play an increasingly
important role in the study and monitoring of combi-
nation therapy for the treatment of HIV infection.
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